Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.46 |
| ▸ | DDX3X | O00571 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | FHIT | P49789 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929452 | 0.87 | AKR1C3 (0.71) | AKR1C3POLBCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2931923 | 0.85 | AKR1C3 (0.57) | AKR1C3POLBCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL1163512 | 0.77 | KMT2A (0.59) | AKR1C3POLBDDX3XKDM4EALDH1A1 | |
| SCHEMBL2925610 | 0.77 | NPC1 (0.63) | AKR1C3POLBDDX3XHDAC6KDM4E | |
| SCHEMBL20685362 | 0.77 | POLB (0.56) | AKR1C3POLBDDX3XCSNK1A1CSNK1D | |
| SCHEMBL2419363 | 0.76 | FHIT (0.66) | POLBKDM4EALDH1A1MAPTFHIT | |
| SCHEMBL20685301 | 0.76 | POLB (0.55) | AKR1C3POLBDDX3XHDAC6KDM4E | |
| SCHEMBL9717917 | 0.75 | RAB9A (0.52) | KDM4EALDH1A1MAPT | |
| SCHEMBL5108887 | 0.75 | ALDH1A1 (0.51) | CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1 | |
| SCHEMBL1965111 | 0.75 | AKR1C3 (0.55) | AKR1C3POLBCSNK2A1DDX3XHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885POLB 1990/4885CSNK2A1 346/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885POLB 1990/4885CSNK2A1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.